Annual General Meeting of Active Biotech AB
The Annual General Meeting of Active Biotech was held on May 5, 2011.
In accordance with the Board of Directors' proposal, it was resolved that no
dividend would be paid.
In accordance with the Election Committee's proposal, the Board members Mats
Arnhög, Klas Kärre, Magnhild Sandberg and Peter Sjöstrand were re-elected. Peter
Hofvenstam, Mef Nilbert and Peter Thelin were elected as Board members. The
Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board.
Furthermore, in accordance with the Election Committee's proposal, the Meeting
resolved that the Election Committee shall be composed of representatives for
the three largest owners, as per end of September, 2011, as well as the Chairman
of the Board.
The Meeting approved the Board's proposal concerning guidelines for remuneration
to the President and other senior executives. The guidelines essentially conform
to the principles applied to date.
In accordance with the Board's proposal, the Meeting resolved to authorize the
Board, for a period that does not extend past the date of the next Annual
General Meeting, to resolve on the issue of not more than six million new shares
and/or convertibles with the corresponding dilution effect, with or without pre-
emptive rights for the company's shareholders.
Finally, pursuant to new provisions in the Swedish Companies Act, the meeting
approved an amendment of the Articles of Association (Section 7), as follows:
Notice of general meetings shall be made through announcement in Post- och
Inrikes Tidningar and on the company's website. It shall be announced in Svenska
Dagbladet that a notice of a general meeting has been issued.
Lund, May 6, 2011
Active Biotech AB (publ)
President and CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy, primarily of
renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on May 6, 2011.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Annual General Meeting of Active Biotech AB:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE